Trial · NCT04057573
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 24-Week Double-Blind Period | STARTED | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 229 | |
| 24-Week Double-Blind Period | STARTED | Double-Blind Period: Vehicle Cream BID | 115 | |
| 24-Week Double-Blind Period | STARTED | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | STARTED | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | ITT Population | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 229 | |
| 24-Week Double-Blind Period | ITT Population | Double-Blind Period: Vehicle Cream BID | 115 | |
| 24-Week Double-Blind Period | ITT Population | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | ITT Population | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | ITT Population, Excluding Non-compliant Site | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 222 | |
| 24-Week Double-Blind Period | ITT Population, Excluding Non-compliant Site | Double-Blind Period: Vehicle Cream BID | 109 | |
| 24-Week Double-Blind Period | ITT Population, Excluding Non-compliant Site | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | ITT Population, Excluding Non-compliant Site | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | COMPLETED | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 199 | |
| 24-Week Double-Blind Period | COMPLETED | Double-Blind Period: Vehicle Cream BID | 98 | |
| 24-Week Double-Blind Period | COMPLETED | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | COMPLETED | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | NOT COMPLETED | Double-Blind Period: Ruxolitinib Cream 1.5% BID | 30 | |
| 24-Week Double-Blind Period | NOT COMPLETED | Double-Blind Period: Vehicle Cream BID | 17 | |
| 24-Week Double-Blind Period | NOT COMPLETED | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | 0 | |
| 24-Week Double-Blind Period | NOT COMPLETED | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04057573/flow